Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fanny Domont

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Circulation|July 7, 2020
Long-Term Outcome and Prognosis Factors of Isolated AortitisYasmina Ferfar, Sarah Morinet, Olivier Espitia, et al.
Ophthalmology|November 18, 2021
Anti-Tumor Necrosis Factor α versus Tocilizumab in the Treatment of Refractory Uveitic Macular Edema: A Multicenter Study from the French Uveitis NetworkMathilde Leclercq, Anaïs Andrillon, Georgina Maalouf, et al.
Ophthalmology|June 8, 2025
Corticosteroids with or without Conventional Disease-Modifying Antirheumatic Drug as First-Line Therapy in Nonanterior Sarcoidosis UveitisRobin Jacquot, Pascal Sève, Guillaume Mulier, et al.
American Journal of Ophthalmology|February 16, 2022
Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 PatientsGeorgina Maalouf, Anaïs Andrillon, Mathilde Leclercq, et al.
Ophthalmology|May 21, 2025
Comparative effectiveness of intravenous versus subcutaneous tocilizumab for refractory uveitis: a retrospective analysisMathilde Leclercq, Robin Jacquot, Camille Charbonnier, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 28, 2025
Deep immunophenotyping and clustering identifies biomarkers predictive of lymphoma in primary Sjögren diseaseCindy Marques, Paul Régnier, Anna Maciejewski-Duval, et al.
The Lancet. Rheumatology|March 31, 2021
COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort studyJérôme Avouac, Elodie Drumez, Eric Hachulla, et al.
Frontiers in Medicine|April 10, 2023
CovAID: Identification of factors associated with severe COVID-19 in patients with inflammatory rheumatism or autoimmune diseasesKevin Chevalier, Michaël Genin, Thomas Petit Jean, et al.
NEJM Evidence|October 22, 2024
Infliximab versus Cyclophosphamide for Severe Behçet's SyndromeDavid Saadoun, Georgina Maalouf, Matheus Vieira, et al.
American Journal of Ophthalmology|February 5, 2026
Adalimumab, Anakinra and Tocilizumab in patients with non-infectious Uveitis: A multicenter randomized controlled trialDavid Saadoun, Amine Ghembaza, Sarah Touhami, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Circulation|July 7, 2020
Long-Term Outcome and Prognosis Factors of Isolated AortitisYasmina Ferfar, Sarah Morinet, Olivier Espitia, et al.
Ophthalmology|November 18, 2021
Anti-Tumor Necrosis Factor α versus Tocilizumab in the Treatment of Refractory Uveitic Macular Edema: A Multicenter Study from the French Uveitis NetworkMathilde Leclercq, Anaïs Andrillon, Georgina Maalouf, et al.
Ophthalmology|June 8, 2025
Corticosteroids with or without Conventional Disease-Modifying Antirheumatic Drug as First-Line Therapy in Nonanterior Sarcoidosis UveitisRobin Jacquot, Pascal Sève, Guillaume Mulier, et al.
American Journal of Ophthalmology|February 16, 2022
Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 PatientsGeorgina Maalouf, Anaïs Andrillon, Mathilde Leclercq, et al.
Ophthalmology|May 21, 2025
Comparative effectiveness of intravenous versus subcutaneous tocilizumab for refractory uveitis: a retrospective analysisMathilde Leclercq, Robin Jacquot, Camille Charbonnier, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 28, 2025
Deep immunophenotyping and clustering identifies biomarkers predictive of lymphoma in primary Sjögren diseaseCindy Marques, Paul Régnier, Anna Maciejewski-Duval, et al.
The Lancet. Rheumatology|March 31, 2021
COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort studyJérôme Avouac, Elodie Drumez, Eric Hachulla, et al.
Frontiers in Medicine|April 10, 2023
CovAID: Identification of factors associated with severe COVID-19 in patients with inflammatory rheumatism or autoimmune diseasesKevin Chevalier, Michaël Genin, Thomas Petit Jean, et al.
NEJM Evidence|October 22, 2024
Infliximab versus Cyclophosphamide for Severe Behçet's SyndromeDavid Saadoun, Georgina Maalouf, Matheus Vieira, et al.
American Journal of Ophthalmology|February 5, 2026
Adalimumab, Anakinra and Tocilizumab in patients with non-infectious Uveitis: A multicenter randomized controlled trialDavid Saadoun, Amine Ghembaza, Sarah Touhami, et al.
Pageof 4